Aldeyra Therapeutics shares rise 2.32% intraday after resubmitting NDA for reproxalap to treat dry eye disease.

Aldeyra Therapeutics, Inc. rose 2.32% intraday, with the company resubmitting a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. The resubmitted NDA included new clinical data from the recently completed dry eye chamber trial, which achieved the primary endpoint.